Prism could save the health insurance industry $20 billion by avoiding paying for ineffective therapies. This test was developed to meet a medical and financial need for patients with autoimmune diseases. Read Article
Scipher's CSO Keith Johnson, PhD and Michael Weinblatt, MD discuss the importance of extending precision medicine from oncology to complex diseases by using PrismRA, a drug response test, to stratify patients based on drugs that are more likely to work adequately for them. Read Article
